Paper Details

  1. Home
  2. Paper Details

Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial Hypertension.

Author: ChannickRichard, ChinKelly M, Di ScalaLilla, GaineSean, GalièNazzareno, GhofraniHossein-Ardeschir, HoeperMarius M, LangIrene M, McLaughlinVallerie V, PreissRalph, RubinLewis J, SimonneauGérald, SitbonOlivier, TapsonVictor F

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

NT-proBNP is a blood test used to assess the severity of pulmonary arterial hypertension (PAH). While it's part of the risk assessment for PAH, its role in predicting outcomes is unclear. This study aims to evaluate the prognostic value of NT-proBNP levels in the GRIPHON trial and how patients with different NT-proBNP levels respond to selexipag, a PAH treatment.
Paper Details　
Original Abstract of the Article :
Label="BACKGROUND">NT-proBNP (N-terminal pro brain natriuretic peptide) levels are included in the multiparametric risk assessment approach for pulmonary arterial hypertension (PAH) outlined in PAH guidelines. However, data supporting the use of NT-proBNP risk thresholds in assessing prognosis in PA...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6530970/

データ提供：米国国立医学図書館（NLM）

NT-proBNP: A Prognostic Beacon in Pulmonary Arterial Hypertension

This research explores the prognostic value of NT-proBNP (N-terminal pro brain natriuretic peptide) levels in patients with pulmonary arterial hypertension (PAH). The study leverages data from the GRIPHON trial, a large clinical trial evaluating the efficacy of selexipag, a PGI2 receptor agonist, in PAH. The researchers investigated the association between NT-proBNP levels and long-term outcomes in PAH patients, specifically examining the response to selexipag based on NT-proBNP thresholds.

NT-proBNP: A Valuable Prognostic Tool for PAH

The study found a significant association between NT-proBNP levels and long-term outcome in PAH patients. The researchers identified specific NT-proBNP thresholds that were predictive of mortality and other adverse events, demonstrating the value of NT-proBNP as a prognostic biomarker in PAH. These findings emphasize the importance of incorporating NT-proBNP into the multiparametric risk assessment approach outlined in PAH guidelines.

Pulmonary Arterial Hypertension: Navigating the Road Ahead

This study highlights the crucial role of NT-proBNP in managing PAH, a complex and often challenging condition. Understanding the prognostic implications of NT-proBNP levels allows healthcare professionals to personalize treatment strategies and provide tailored care for individual patients. Early identification and timely interventions can significantly improve outcomes and enhance quality of life for PAH patients.

Dr. Camel's Conclusion

This research reveals the significant prognostic value of NT-proBNP in patients with PAH. By incorporating NT-proBNP into the multiparametric risk assessment approach, healthcare professionals can better personalize treatment strategies and guide patients toward optimal outcomes. The study underscores the importance of early identification and prompt intervention in managing this complex and often challenging condition.
Date :
  1. Date Completed 2020-03-02
  2. Date Revised 2020-03-09
Further Info :

Pubmed ID

30982349

DOI: Digital Object Identifier

PMC6530970

Related Literature

Article Analysis
・Effects of selexipag
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.